Skip to main content
SpringerLink
Log in

Topical BVDU plus low-dosage steroids in the treatment of chronic relapsing zoster keratouveitis

A pilot study

  • Clinical Investigations
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

A therapeutic trial with topical bromovinyldeoxy- uridine (BVDU) plus low-dosage steroids was conducted in five patients with chronic zoster keratouveitis, who had previously received topical acyclovir (ACV) and steroids. In all cases, BVDU (plus steroids) was found to be superior to ACV (plus steroids). Yet BVDU was not able to keep the patients from having chronic relapsing varicella-zoster keratouveitis. This can probably be explained by pathophysiological reasons, i.e., the persistence and low-grade multiplication of the varicella-zoster virus in peripheral eye tissues during the chronic carrier stage. It is possible that this chronic carrier status could be obviated by vigorous antiviral treatment during the acute phase of the illness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boisjoly HM, Park N-H, Pavan-Langston D, De Clercq E (1983) Herpes simplex acyclovir-resistant mutant in experimental keratouveitis. Arch Ophthalmol 101:1782–1786

    Google Scholar 

  2. De Clercq E (1984) Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)- 2′-deoxyuridine and related compounds. Antimicrob Agents Chemother 26:155–159

    Google Scholar 

  3. De Clercq E, Descamps J, Barr PJ, Jones AS, Serafinowski P, Walker RT, Huang GF, Torrence PF, Schmidt CL, Mertens MP, Kulinowski T, Shugar D (1979) Comparative study of the potency and selectivity of anti-herpes compounds. In: Skoda J, Langen P (eds) Antimetabolites in biochemistry, biology and medicine. Pergamon Press, Oxford, pp 275–285

    Google Scholar 

  4. De Clercq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT (1979) (E)-5-(2-bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci USA 76:2947–2951

    Google Scholar 

  5. De Clercq E, Descamps J, Maudgal PC, Missotten L, Leyten R, Verhelst G, Jones AS, Walker RT, Busson R, Vanderhaeghe H, De Somer P (1980) Selective anti-herpes activity of 5-(2-halogenovinyl) -2′-deoxyuridines and -2′-deoxycytidines. In: Collier LH, Oxfort J (eds) Developments in antiviral therapy. Academic Press, London, pp 21–42

    Google Scholar 

  6. De Clercq E, Descamps J, Verhelst G, Walker RT, Jones AS, Torrence PF, Shugar D (1980) Comparative efficacy of anti-herpes drugs against different strains of herpes simplex virus. J Infect Dis 141:563–574

    Google Scholar 

  7. De Clercq E, Zhang Z-X, Descamps J, Huggen K (1981)E-5-(2-bromovinyl)-2′-deoxyuridine vs. interferon in the systemic treatment of infection with herpes simplex virus of athymic nude mice. J Infect Dis 143:846–852

    Google Scholar 

  8. De Clercq E, Descamps J, Ogata M, Shigeta S (1982) In vitro susceptibility of varicella-zoster virus toE-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob Agents Chemother 21:33–38

    Google Scholar 

  9. De Clercq E, Zhang Z-X, Sim IS (1982) Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2′-deoxyuridine in mice. Antimicrob Agents Chemother 22:421–425

    Google Scholar 

  10. Maudgal PC, De Clercq E (1985) Evaluation of bromovinyl-deoxyuridine-related compounds in the treatment of experimental herpes simplex keratitis. Arch Ophthalmol 103:1393–1397

    Google Scholar 

  11. Maudgal PC, De Clercq E, Descamps J, Missotten L (1979) Comparative evaluation of BVDU (E)-5-(2-bromovinyl)-2′-deoxyuridine and IDU (5-iodo-2′-deoxyuridine) in the treatment of experimental herpes simplex keratitis in rabbits. Bull Soc Beige Ophtalmol 186:109–118

    Google Scholar 

  12. Maudgal PC, De Clercq E, Descamps J, Missotten L, De Somer P, Busson R, Vanderhaeghe H, Verhelst G, Walker RT, Jones AS (1980) (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex keratitis. Antimicrob Agents Chemother 17:8–12

    Google Scholar 

  13. Maudgal PC, Dralands L, Lamberts L, De Clercq E, Descamps J, Missotten L (1981) Preliminary results of oral BVDU treatment of herpes zotes ophthalmicus. Bull Soc Beige Ophtalmol 193:49–56

    Google Scholar 

  14. Maudgal PC, De Clercq E, Descamps J, Missotten L, Wijnhoven J (1982) Experimental stromal herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine. Arch Ophthalmol 100:653–656

    Google Scholar 

  15. Maudgal PC, Uyttebroeck W, De Clercq E, Missotten L (1982) Oral and topical treatment of experimental herpes simplex iritis with bromovinyldeoxyuridine. Arch Ophthalmol 100:1337–1340

    Google Scholar 

  16. Maudgal PC, De Clercq E, Descamps J, Missotten L (1984) Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir. A water-soluble ester of acyclovir. Arch Ophthalmol 102:140–142

    Google Scholar 

  17. Maudgal PC, De Clercq E, Missotten L (1984) Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus in eye infections. Antiviral Res 4:281–291

    Google Scholar 

  18. Maudgal PC, Dieltiens M, De Clercq E, Missotten L (1985) Oral bromovinyldeoxyuridine treatment of herpes zoster ophthalmicus. In: Maudgal PC, Missotten L (eds) Herpetic eye diseases. Junk, Dordrecht, pp 403–407

    Google Scholar 

  19. Maudgal PC, Verbruggen AM, De Clercq E, Busson R, Bernaerts R, Roo M de, Ameye C, Missotten L (1985) Ocular penetration of (125 I) IVDU, a radiolabeled analogue of bromovinyldeoxyuridine. Invest Ophthalmol Vis Sci 26: 45–49

    Google Scholar 

  20. Maudgal PC, Dieltiens M, De Clercq E, Missotten L (1985) Topical bromovinyldeoxyuridine treatment of herpes simplex keratitis. In: Maudgal PC, Missotten L (eds) Herpetic eye diseases. Junk, Dordrecht, pp 247–255

    Google Scholar 

  21. Meurs PJ, Bijsterveld OP van (1986) Bromovinyldeoxyuridine and acyclovir in combination with recombinant human alpha 2 interferon as treatment for dendritic keratitis. International Conference on Herpetic Eye Diseases, September 6–8, 1986, North Lake Tahoe, Calif

  22. Park NH, Pavan-Langston D, Boisjoly HM, De Clercq E (1982) Chemotherapeutic efficacy ofE-5-(2-bromovinyl)-2′-deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice. J Infect Dis 145:909–913

    Google Scholar 

  23. Park NH, Pavan-Langston D, De Clercq E (1983) Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice. Antiviral Res 3:7–15

    Google Scholar 

  24. Shigeta S, Yokota T, Iwabuchi I, Baba M, Konno K, Ogata M, De Clercq E (1983) Comparative efficacy of anti-herpes drugs against various strains of varicella-zoster virus. J Infect Dis 147:576–584

    Google Scholar 

  25. Sim IS (1984) Oral and topical treatment of experimental HSV-1 genital herpes with (E)-5-(2-bromovinyl)-2′-deoxyuridine. J Antimicrob Chemother [Suppl A] 14:111–118

    Google Scholar 

  26. Soike KF, Gibson S, Gerone PJ (1981) Inhibition of simian varicella virus infection of African green monkeys by (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). Antiviral Res 1: 325–327

    Google Scholar 

  27. Tricot G, De Clercq E, Boogaerts MA, Verwilghen RL (1986) Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial. J Med Virol 18:11–20

    Google Scholar 

  28. Wildiers J, De Clercq E (1984) Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine treatment of severe herpes zoster in cancer patients. Eur J Cancer Clin Oncol 20:471–476

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Augenklinik, Moorenstrasse 5, D-4000, Düsseldorf, Federal Republic of Germany

    C. Ameye & R. Sundmacher

  2. Rega Institute for Medical Research, University of Leuven, B-3000, Leuven, Belgium

    E. de Clercq

Authors
  1. C. Ameye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Sundmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. de Clercq
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ameye, C., Sundmacher, R. & de Clercq, E. Topical BVDU plus low-dosage steroids in the treatment of chronic relapsing zoster keratouveitis. Graefe's Arch Clin Exp Ophthalmol 227, 118–122 (1989). https://doi.org/10.1007/BF02169782

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02169782

Keywords

Search

Navigation